Triple subunit vaccine for porcine epidemic diarrhea virus, porcine delta coronavirus and porcine transmissible gastroenteritis virus

CN118903401APending Publication Date: 2024-11-08HENAN AGRICULTURAL UNIVERSITY
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411289486.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

[0005]截止目前,我国现有的PEDV和TGEV防控疫苗主要是以灭活疫苗和弱毒疫苗为主,PDCoV未有商品化疫苗,能够实现同时预防PEDV、TGEV及PDCoV的三联亚单位疫苗制作方法还未见报道

Benefits of technology

[0022] The invention provides a triple subunit vaccine of porcine epidemic diarrhea virus, porcine delta coronavirus and porcine transmissible gastroenteritis virus. There is currently no triple subunit vaccine for porcine epidemic diarrhea virus, porcine delta coronavirus, and porcine transmissible gastroenteritis virus. The present invention uses a safe and efficient insect-baculovirus eukaryotic expression system, and effectively improves the protein expression level through artificial codon optimization. The structural state of the recombinant protein obtained is completely consistent with the natural structural state, and the function of the protein is retained to the greatest extent. and immunogenicity. The triple subunit vaccine of the present invention has simple ingredients, is safe, has many antiviral types and has good immune effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903401A_ABST
    Figure CN118903401A_ABST
Patent Text Reader

Abstract

The invention provides a triple subunit vaccine for porcine epidemic diarrhea virus, porcine delta coronavirus and porcine transmissible gastroenteritis virus, and particularly belongs to the technical field of vaccine preparation. The invention provides a triple subunit vaccine. The triple subunit vaccine comprises an antigen and an immunologic adjuvant, the antigen comprises a porcine epidemic diarrhea virus SCOE protein, a porcine delta coronavirus SRBD protein and a porcine transmissible gastroenteritis virus SAD protein. The triplet subunit vaccine is good in antigen immunogenicity and good in vaccine prevention effect, and compared with a single vaccine, the prepared triplet subunit vaccine can reduce labor cost, reduce the number of times of vaccine immunization and inoculation, simplify complicated immunization procedures, reduce stress reaction generated by immunization, remarkably reduce production cost and improve the production efficiency. A series of potential safety hazards such as toxin leakage, virulence enhancement and incomplete inactivation are avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of vaccine preparation, and specifically relates to a triple subunit vaccine of porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus. Background Art

[0002] Porcine Epidemic Diarrhea Virus (PEDV) was first detected in 1970. The disease can occur all year round, but is more common in winter. PEDV only infects pigs, and pigs of all ages are susceptible. The incubation period is generally 2 to 4 days, and the shortest is only 12 hours. It often appears in the form of explosive diarrhea. The symptoms are most severe after piglets are infected, and they usually die of dehydration within 2 to 4 days after diarrhea occurs.

[0003] Porcine DeltacoronaVirus mainly infects piglets, showing clinical symptoms such as vomiting, diarrhea, dehydration, and atrophy, shortening, and shedding of the villi in the jejunum and ileum. PDCoV has a global epidemic trend, causing huge losses to the pig industry.

[0004] Transmissible gastroenteritis of swine (TGE) is caused by TGEV of the Coronavirus family and is an acute, highly contagious enteric disease. The symptoms of pigs of different ages after infection vary. For piglets under 10 days old, vomiting often occurs within 24 hours after infection, followed by severe watery or pasty diarrhea, and the feces are yellow and contain undigested curds. These piglets lose weight rapidly, have obvious symptoms of dehydration, and usually die within 2 to 7 days after onset, with a mortality rate of up to 100%.

[0005] Up to now, the existing PEDV and TGEV prevention and control vaccines in my country are mainly inactivated vaccines and attenuated vaccines. There is no commercialized vaccine for PDCoV, and the method for producing a triple subunit vaccine that can simultaneously prevent PEDV, TGEV and PDCoV has not been reported. Summary of the invention

[0006] The purpose of the present invention is to provide a triple subunit vaccine for porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus. The triple subunit vaccine of the present invention can simultaneously prevent diseases caused by porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus, is safe and has good immune effect.

[0007] The present invention provides a triple subunit vaccine of porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus, wherein the triple subunit vaccine comprises an antigen and an immune adjuvant; the antigen comprises porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD protein.

[0008] Preferably, the protein encoding porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD The nucleotide sequences of the protein genes after optimization of baculovirus codon preference are SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively.

[0009] Preferably, the porcine epidemic diarrhea virus S in the triple subunit vaccine COE Protein, porcine deltacoronavirus S RBD TGEV-S AD The mass ratio of the proteins is (2~4):(2~4):(2~4).

[0010] Preferably, in each dose of the triple subunit vaccine, porcine epidemic diarrhea virus S COE The amount of protein used is 20-40 μg, porcine delta coronavirus S RBD The dosage of protein is 20-40 μg, and the amount of porcine transmissible gastroenteritis virus S AD The amount of protein used is 20 to 40 μg.

[0011] Preferably, the immune adjuvant comprises ISA201 VG adjuvant and CPG 2395 immune enhancer.

[0012] Preferably, the mass ratio of ISA201 VG adjuvant to antigen is 1:1; and the volume percentage of CPG 2395 immune enhancer added is 5%.

[0013] Preferably, the pH value of the triple subunit vaccine is 7.6-8.2.

[0014] The present invention also provides a method for preparing the triple subunit vaccine described in the above technical solution, comprising the following steps:

[0015] Under sterile conditions, the antigen and immune adjuvant are mixed to obtain a triple subunit vaccine.

[0016] Preferably, the method for preparing the antigen comprises the following steps:

[0017] The gene sequences of the antigens after baculovirus codon preference optimization were cloned into baculovirus transfer vectors to obtain recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD;

[0018] The recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD are respectively transferred into competent cells DH10Bac, cultured, screened, and extracted to obtain recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD;

[0019] The recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD were transfected into SF9 cells, respectively, to rescue the recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD;

[0020] The recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD were inoculated into Hi-five cells, the cells were ultrasonically disrupted, the supernatant was centrifuged and the antigen PEDV-S was obtained by ion exchange chromatography. COE Protein, PDCoV-S RBD Protein and TGEV-S AD protein.

[0021] Preferably, the immune adjuvant comprises ISA201 VG adjuvant and CPG 2395 immune enhancer, the mass ratio of ISA201 VG adjuvant to antigen is 1:1; and the volume percentage of CPG 2395 immune enhancer added is 5%.

[0022] The present invention provides a triple subunit vaccine for porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus. Currently, there is no triple subunit vaccine for porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus. The present invention uses a safe and efficient insect-baculovirus eukaryotic expression system, and effectively improves the protein expression level through artificial codon optimization. The obtained recombinant protein structure state is completely consistent with the natural structure state, and the function and immunogenicity of the protein are retained to the greatest extent. The triple subunit vaccine of the present invention has simple ingredients, is safe, has a wide range of antiviral types, and has a good immune effect.

[0023] Compared with single vaccines, the triple subunit vaccine of porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus prepared by the present invention can reduce labor costs, reduce the number of vaccine immunizations, simplify complicated immunization procedures, reduce stress reactions caused by immunization, significantly reduce production costs, and avoid a series of safety hazards such as toxin leakage, virulence reversion, and incomplete inactivation. The test results show that the triple subunit vaccine of PEDV, PDCoV and TGEV of the present invention can produce significant immune effects in mice by immunizing mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0025] Figure 1 The PCR identification diagram of the recombinant plasmid provided by the present invention; wherein A is the PCR identification diagram of the pFastbacHTA-COE plasmid, B is the PCR identification diagram of the pFastbacHTA-RBD plasmid, and C is the PCR identification diagram of the pFastbacHTA-SAD plasmid;

[0026] Figure 2 The PEDV S provided by the present invention COE Protein SDS-PAGE (A) and Western blot (B) protein expression identification diagram;

[0027] Figure 3 PDCoV S provided by the present invention RBD Protein SDS-PAGE (A) and Western blot (B) protein expression identification diagram;

[0028] Figure 4 The TGEV S provided by the present invention AD Protein SDS-PAGE (A) and Western blot (B) protein expression identification;

[0029] Figure 5 This is the SDS-PAGE identification diagram of the recombinant protein purification result provided by the present invention; wherein A is PEDV-S COE Protein purification and identification diagram; B is PDCoV-S RBD Protein purification and identification diagram; C is TGEV-S AD Protein purification and identification diagram;

[0030] Figure 6The results of the mouse serum specific antibody level detection provided by the present invention are shown in Figure 1; wherein A is a PEDV-specific IgG antibody detection diagram; B is a PDCoV-specific IgG antibody detection diagram; and C is a TGEV-specific IgG antibody detection diagram;

[0031] Figure 7 The test results of mouse serum neutralizing antibodies provided by the present invention are shown in Figure 1; wherein A is a PEDV neutralizing antibody test diagram; B is a PDCoV neutralizing antibody test diagram; and C is a TGEV neutralizing antibody test diagram;

[0032] Figure 8 The graphs of the mouse cytokine level detection results provided by the present invention; wherein A is a graph of the IFN-γ level detection of mice after immunization; B is a graph of the IL-2 level detection of mice after immunization; C is a graph of the IL-5 level detection of mice after immunization;

[0033] Fig. 9 The mouse lymphocyte proliferation test result diagram provided by the present invention; wherein A is PEDV-S COE Protein stimulated mouse lymphocyte proliferation detection diagram; B is PDCoV-S RBD Protein stimulated mouse lymphocyte proliferation detection diagram; C is TGEV-S AD Protein stimulated mouse lymphocyte proliferation detection diagram;

[0034] Fig.10 The mouse spleen-specific CTL activity detection result diagram provided by the present invention; wherein A is a PEDV mouse spleen-specific CTL activity detection diagram; B is a PDCoV mouse spleen-specific CTL activity detection diagram; C is a TGEV mouse spleen-specific CTL activity detection diagram;

[0035] Fig.11 CD4 in mouse spleen lymphocytes provided by the present invention + T cell content result diagram; A is CD4 before in vitro stimulation + T cell content diagram; B is CD4 after in vitro stimulation + T cell content diagram; C is CD4 before and after in vitro stimulation + T cell content graph;

[0036] Fig.12 CD8 in mouse spleen lymphocytes provided by the present invention + T cell content results; A is CD8 before in vitro stimulation + T cell content diagram; B is CD8 after in vitro stimulation + T cell content diagram; C is CD8 before and after in vitro stimulation + T cell content graph. DETAILED DESCRIPTION

[0037] The present invention provides a triple subunit vaccine of porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus, wherein the triple subunit vaccine comprises an antigen and an immune adjuvant; the antigen comprises porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD In the present invention, the protein encoding porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD The nucleotide sequences of the protein genes after optimization of baculovirus codon preference are SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively. The antigens of the present invention are derived from the COE sequence of porcine epidemic diarrhea virus S protein (PEDV-S COE ), porcine deltacoronavirus S protein RBD sequence (PDCoV-S RBD ) and porcine transmissible gastroenteritis virus S protein A, D sequence (TGEV-S AD ). The S1 protein of PDCoV has similar functions to the S1 proteins of other coronaviruses. It plays an important role in binding of the virus to cell receptors, mediating cell adhesion, and promoting fusion of the virus and cell membranes. As part of the S1 protein, the receptor binding domain (RBD) can bind to the host cell aminopeptidase N (Aminopeptidase N, APN) receptor, which is of great significance for mediating virus invasion. RBD is the domain with the strongest neutralizing effect in S1. As a vital structural protein in TGEV, the S protein is the only key molecule that can trigger the production of neutralizing antibodies and confer immune protection when the body is infected with TGEV. There are four major antigenic sites A, B, C and D at the N-terminus of the TGEV S protein. The S gene fragment containing the four antigenic sites induces virus neutralizing antibody titers that are comparable to those induced by the complete S protein. The genes encoding the antigenic sites are mainly present in the A region and partially in the D region. Site A is the main site for inducing neutralizing antibodies and is highly conserved. The present invention uses a safe, efficient, and safe insect-baculovirus eukaryotic expression system, and effectively improves the protein expression level through artificial codon optimization. The obtained recombinant protein structure is completely consistent with the natural structure, and the protein function and immunogenicity are retained to the greatest extent.

[0038] In the present invention, the porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S ADThe mass ratio of the proteins is preferably (2-4): (2-4): (2-4). In the present invention, the porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD The mass ratio of the proteins is more preferably 1:1:1. In the present invention, in each dose of the triple subunit vaccine, porcine epidemic diarrhea virus S COE The amount of protein used is preferably 20 to 40 μg, more preferably 30 μg, porcine deltacoronavirus S RBD The amount of protein is 20-40 μg, more preferably 30 μg, porcine transmissible gastroenteritis virus S AD The amount of protein is 20 to 40 μg, more preferably 30 μg. In the present invention, the immune adjuvant preferably includes ISA201 VG adjuvant and CPG 2395 immunoenhancer. In the present invention, the ISA201 VG adjuvant is preferably purchased from Seppic (Shanghai) Special Chemicals Co., Ltd. In the present invention, the CPG 2395 immunoenhancer is preferably purchased from Wuhan Aoke Dingsheng Biotechnology Co., Ltd. In the present invention, the mass ratio of ISA201 VG adjuvant to antigen is preferably 1:1; the volume percentage of CPG 2395 immunoenhancer added is 5%. In the present invention, the pH value of the triple subunit vaccine is 7.6 to 8.2. The present invention adopts a multi-component mixing method to keep the original antigenic characteristics of each component in structure. The vaccine has a white or off-white milky suspension appearance, is stored at 2 to 8 ° C, and is inoculated within the specified dosage. There is no obvious toxic reaction to experimental animals and it can produce a significant immune response in the experimental animals.

[0039] The present invention also provides a method for preparing the triple subunit vaccine described in the above technical solution, comprising the following steps: under sterile conditions, mixing the antigen and the immune adjuvant to obtain the triple subunit vaccine.

[0040] In the present invention, the method for preparing the antigen preferably comprises the following steps:

[0041] The gene sequences of the antigens after baculovirus codon preference optimization were cloned into baculovirus transfer vectors to obtain recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD;

[0042] The recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD are respectively transferred into competent cells DH10Bac, cultured, screened, and extracted to obtain recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD;

[0043] The recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD were transfected into SF9 cells, respectively, to rescue the recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD;

[0044] The recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD were inoculated into Hi-five cells, the cells were ultrasonically disrupted, the supernatant was centrifuged and the antigen PEDV-S was obtained by ion exchange chromatography. COE Protein, PDCoV-S RBD Protein and TGEV-S AD protein.

[0045] The present invention clones the gene sequences of antigens after baculovirus codon preference optimization into baculovirus transfer vectors to obtain recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD. Codon optimization is performed on porcine epidemic diarrhea virus (PEDV) S protein COE sequence, porcine deltacoronavirus (PDCoV) S protein RBD sequence, and porcine transmissible gastroenteritis virus (TGEV) S protein A and D sequences according to the codon preference of baculovirus.

[0046] After obtaining the recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD, the present invention transfers the recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD into competent cells DH10Bac, culture, screen and extract to obtain recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD. The present invention does not specifically limit the method of transfer, and a conventional thermal conversion method can be used. For example, after an ice bath for 15 to 30 minutes, heat shock at 42°C for 30 seconds, and ice bath again for 5 to 15 minutes. After thermal conversion, the present invention preferably adds the thermally converted cells to a non-resistant LB liquid culture medium for culture, and then screens the positive colonies by blue-white staining. The present invention extracts the positive colonies to obtain recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD.

[0047] After obtaining the recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD, the present invention transfects the recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD into SF9 cells respectively, and rescues the recombinant baculovirus AcMNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD. After transfection into SF9 cells, the present invention preferably cultures at 27°C, and after 72 hours, the cells undergo complete pathological changes, and the recombinant baculovirus Ac MNPV-COE, Ac MNPV-RBD and AcMNPV-SAD are rescued from the cells.

[0048] After rescuing the recombinant baculovirus Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD, the present invention inoculates the recombinant baculovirus Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD into Hi-five cells, respectively, and the cells are subjected to ultrasonic disruption, centrifuged to obtain the supernatant, and the antigen PEDV-COE protein, PDCoV-RBD protein and TGEV-SAD protein are obtained by ion exchange chromatography. After infection, the present invention preferably collects the centrifuged cells after 72 to 96 hours, and ultrasonic disruption is performed after resuspension. In the present invention, the resuspension preferably uses 0.25mM Hepes (pH=8.2) buffer. The ultrasonic disruption treatment of the present invention is preferably carried out in an ice-water mixture. In the present invention, the conditions of the ultrasonic disruption treatment are preferably: power 100W, work 2s, rest 5s, work 20min. The conditions for centrifugation after ultrasound in the present invention are preferably 12000g centrifugation for 30min. The present invention has no particular limitation on the ion exchange chromatography method, and conventional methods and conditions may be used.

[0049] In the present invention, the immune adjuvant preferably includes ISA201 VG adjuvant and CPG 2395 immune enhancer, and the mass ratio of ISA201 VG adjuvant to antigen is preferably 1:1; the volume percentage of CPG 2395 immune enhancer added is preferably 5%.

[0050] After obtaining the antigen, the present invention preferably uses PEDV-S COE Protein, PDCoV-S RBD Protein, TGEV-S AD The proteins are mixed in equal mass, and the mixed proteins and sterile adjuvant are preferably mixed again in a mass ratio of 1:1, and CPG2395 immunopotentiator is added at 5% of the final volume for emulsification and mixing to prepare a trivalent subunit vaccine. The present invention preferably makes the PEDV-S in each vaccine injection COE Protein, PDCoV-S RBD Protein, TGEV-S AD The protein content is 20-40 μg / dose, and more preferably 30 μg / dose.

[0051] Compared with single vaccines, the triple subunit vaccine of porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus prepared by the present invention can reduce labor costs, reduce the number of vaccine immunizations, simplify complicated immunization procedures, reduce the stress response caused by immunization, significantly reduce production costs, and avoid a series of safety hazards such as toxin leakage, virulence recurrence, and incomplete inactivation.

[0052] To further illustrate the present invention, a triple subunit vaccine of porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus provided by the present invention is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0053] Example 1

[0054] Construction of recombinant baculovirus expression system

[0055] 1. PEDV-S COE PDCoV-S RBD TGEV-S AD Gene codon optimization and synthesis

[0056] According to the COE (499aa-638aa) gene sequence of the PEDV epidemic strain (GenBank: OR707084.1), the RBD (292aa-429aa) gene sequence of PDCoVHNZK-02 (GenBank: MH708123.1), and the SAD (352aa-606aa) gene sequence of TGEV HN-2012 (GenBank: OP434397.1), 10 His tags, promoters, and terminators were added before and after the gene sequences, and the following PEDV-S were synthesized after codon optimization. COE PDCoV-S RBD TGEV-S AD sequence.

[0057] PEDV-S COEOptimized gene sequence (SEQ ID NO.1): ATG CAC CAC CAC CAT CAC CAT CACCAT CAC CAC ACT CTG CCT TCC TTC AAC GAC CAC TCT TTCGTT AAC ATC ACT GTG TCTGCT GCT TTC GGT GGT CAC TCC GGT GCTAAC CTG ATC GCT TCT GAC ACA ACA ATC AACGGT TTC TCT AGC TTCTGC GTT GAC ACA CGT CAG TTC ACA ATC ACC CTG TTC TAC AACGTGACT AAC TCC TAC GGT TAC GTT AGC AAG TCC CAG GAC TCT AAC TGTCCT TTC ACT CTGCAA TCA GTT AAC GAC TAC CTG AGC TTC TCT AAGTTC TGT GTG AGC ACT AGC TTG TTGGCT GGC GCC TGT ACC ATC GACCTG TTC GGT TAC CCT GAA TTC GGT AGC GGT GTG AAGTTC ACT TCTCTG TAC TTC CAG TTC ACT AAG GGT GAA TTG ATC ACA GGT ACA CCTAAG CCTCTG CAG GGT GTG ACT GAC GTG AGC CAT CAC CAC CAC CACCAC CAT CAC CAC CAC TAA。

[0058] PDCoV-S RBDOptimized gene sequence (SEQ ID NO.2): ATG CAC CAC CAT CAC CAC CAT CACCAC CAC CAT CAG CGT ACT ATC GTG ACC CTG CCT AAGCTG CCT GAA CTG GAA GTG GTTCAG CTG AAC ATC TCC GCT CAC ATGGAC TTC GGT GAA GCT CGT CTG GAC AGC GTG ACTATC AAC GGT AACACA TCC TAC TGT GTT ACA AAG CCT TAC TTC CGT CTG GAA ACT AACTTCATG TGT ACC GGT TGC ACT ATG AAC CTG CGT ACT GAC ACA TGTTCC TTC GAC CTG TCCGCT GTT AAC AAC GGT ATG AGC TTC AGC CAGTTC TGT CTC TCT ACC GAA TCC GGT GCTTGT GAA ATG AAG ATC ATCGTG ACA TAC GTT TGG AAC TAC CTG CTG CGT CAG CGT CTGTAC GTGACA GCT GTG GAA GGT CAG ACA CAC ACT GGT ACAACT AGC GTT CACGCTACT GACACT AGC TCC GTT ATC ACA CAC CAC CAC CAC CAT CATCAC CAC CAC CAC TAA。

[0059] TGEV-S ADOptimized gene sequence (SEQ ID NO.3): ATG CAC CAC CAT CAC CAC CAT CACCAC CAC CAT AGC GGC AAG GGT GCC ACC GTG TTC AGC CTGAAC ACC ACC GGT GGT GTGACC CTG GAC ATC TCT TGC TAC AAG GACACA GTG TCC GAC AGC AGC TTC TCC TCC TACGGT GAA ATG CCT TTCGGC GTG ACC GAC GGC CCT CGC CAC TGT TAC GTG CTG TAC AAGGGTACC GCC CTC AAG TAC CTG GGAACC CTG CCT CCT GTG GTG AAG GAGATC GCC ATC AGCAAG TGG GGT CAC TTC TAC ATC AAC GGT TAC AACTTC TTC AGC ACA TTC CCT ATC GACTGC ATC AGC TTC AAC CTG ACAACC GGC GAC TCC GAC GTG TTC TGG ACC ATC GCT TACACT AGC TACACT GAA GCT CTG GTT CAG GTG GAG AAC ACA GCTATCACTAAG GTGACC TACTGT AAC TCC TAC GTG AAC AAC ATC AAG TGC AGC CAG CTGACC GCC AAC CTG AAC AACGGT TTC TAC CCA GTGAGC TCC AGC GAGGTG GGC ATC GTG AAC AAG TCC GTG GTG CTG CTGCCTAGC TTC TACACA CAC ACC ATC GTG AAC ATC ACT ATC GGC CTG GGT ATG AAG CGTTCCGGC TAC GGT CAG CCT ATC GCT TCAACC CTG TCT AAC ATC ACCCTG CCT ATG CAG GGT GACAAC ACC GAC GTG TAC TGT ATC CCT AGCGAC CGT TTC AGC GTG TAC GTG CAC TCC ACCTGTAAG AGC GCC CTGTGG GAC AAC GTT TTC AAG CGTAAGTGTAAG GAC GTG CTG GACGCTACC GCT GTG ATC AAG CAC CAC CAC CAC CAT CAT CAC CAC CAC CACTAA.

[0060] 2. Construction of recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD, and pFastbacHTA-SAD

[0061] (1) PEDV-S COE PDCoV-S RBD TGEV-S AD The target gene was connected to the pFastbacHTA plasmid by homologous recombination, and the reaction system is shown in Table 1.

[0062] Table 1 Reaction system

[0063]

[0064] The above system was connected at 37°C for 30 min; the connected product can be used directly for transformation.

[0065] (2) Transformation: The ligation product was transferred into competent E. coli cells DH5α, plated and inoculated on Amp+ solid medium, and cultured at 37°C for 6 to 8 h.

[0066] (3) Identification of recombinant plasmids pFastbacHTA-COE, pFastbacHTA-RBD, and pFastbacHTA-SAD. Single clones were picked from the plates and identified by bacterial liquid PCR. The primers were pFastbacHTA universal primers. The results showed that the recombinant plasmids were successfully constructed. Figure 1 As shown, A is the PCR identification diagram of pFastbacHTA-COE plasmid, B is the PCR identification diagram of pFastbacHTA-RBD plasmid, and C is the PCR identification diagram of pFastbacHTA-SAD plasmid.

[0067] 3. Construction of recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD, and Ac MNPV-SAD

[0068] (1) The recombinant baculovirus vector constructed in Experiment 2 of Example 1 was taken and the recombinant transfer plasmid was obtained by a small extraction plasmid kit and transferred into the competent cell DH10Bac, stabilized in an ice-water mixture for 15 minutes, heat-shocked at 42°C for 30 seconds, and ice-water bathed for 15 minutes. The LB medium was added and cultured on a shaker for 6 hours. After the bacterial solution was diluted, it was mixed with IPTG and X-Gal, and spread on an LB plate containing antibiotics kanamycin, gentamicin, and tetracycline, cultured for 48 to 72 hours, and screened by blue-white screening.

[0069] (2) The verified recombinant Bacmid was transfected into SF9 cells using CellfectinII Reagent and cultured at 27°C for 72 hours. The recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD, and AcMNPV-SAD were obtained by collecting the cell supernatant after the disease.

[0070] Example 2

[0071] Target protein PEDV-S COE PDCoV-S RBD TGEV-S AD Expression and purification of

[0072] 1. Target protein PEDV-S COE PDCoV-S RBD TGEV-S AD Expression

[0073] (1) The recombinant baculovirus rescued in Example 1 was inoculated into Hi-five cells in suspension culture at an MOI of 1 and a cell density of 1×10 6 cells / ml. After 72 hours, centrifuge at 500g for 10min, discard the supernatant, collect the cells, concentrate 6 times and resuspend the cells, place them in an ice-water mixture and ultrasonically disrupt them: power 100W, work 2s, rest 5s, work 20min. Centrifuge at 12000g for 30min, harvest the cell supernatant for Western blotting and SDS-PAGE to detect protein expression. Figure 2 A and Figure 2 B in the figure indicates the target protein PEDV-S COE Can express, Figure 3 A and Figure 3 B in the figure indicates the target protein PDCoV-S RBD Can express, Figure 4 A and Figure 4 B in the figure indicates the target protein TGEV-S AD Can express.

[0074] 2. Purification of target protein

[0075] The protein was purified by anion and cation exchange method. The specific steps are as follows:

[0076] (1) Take the cell culture medium 72 hours after infection and centrifuge it at 500g for 10 minutes, discard the supernatant, collect the cells, concentrate them 6 times and resuspend them, and place them in an ice-water mixture for ultrasonic disruption: power 100W, work 2s, rest 5s, work 20min. Centrifuge at 12000g for 30min, harvest the cell supernatant and filter it with a 0.45μm filter membrane to remove fine impurities. After filtration, incubate it with anion exchange medium for 1h, and use different concentrations of elution buffer (0.01MNaCl, 0.06MNaCl, 0.15MNaCl, 0.2MNaCl, 0.3MNaCl, 0.4MNaCl) to elute through the column to obtain the target protein. The results are as follows Figure 5 A in Figure 5 B and Figure 5 As shown in C.

[0077] (2) The target protein was concentrated and replaced using a 10 kDa ultrafiltration tube, and the protein concentration was detected using a BCA protein detection kit. COE The protein content reached 4.7 mg / mL and the purity reached 91.3%; PDCoV-S RBD The protein content reached 5.6 mg / mL and the purity reached 95.3%; TGEV-S AD The protein content reached 3.6 mg / mL and the purity reached 90.4%.

[0078] Example 3

[0079] Preparation of a triple subunit vaccine against porcine epidemic diarrhea virus, porcine deltacoronavirus, and porcine transmissible gastroenteritis virus

[0080] 1. PEDV-S purified in Example 2 COE Protein, PDCoV-S RBD Protein, TGEV-S AD After the protein is calculated according to the purity ratio, 30 μg of protein is extracted and mixed evenly, and mixed with ISA201 VG adjuvant at a mass ratio of 1:1 under sterile operation. CPG 2395 immune enhancer is added at 5% of the final volume to emulsify and mix to prepare a trivalent subunit vaccine. The content of each protein in each dose of vaccine is 30 μg / dose, and it is stored at 4°C for use.

[0081] Example 4

[0082] Safety and immune efficacy test of triple subunit vaccine against porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus in mice

[0083] 1. Safety test of triple subunit vaccine against porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus in mice

[0084] (1) Twelve 6-week-old female Balb / C mice were purchased and randomly divided into two groups, A and B, with 6 mice in each group. Each mouse in group A was subcutaneously injected with 0.2 ml of the triple subunit vaccine prepared in Example 3; each mouse in group B was subcutaneously injected with 0.2 ml of PBS buffer solution; continuous observation and recording for 2 weeks showed that the mice in both groups ate and drank normally without abnormal reactions. This indicates that the triple subunit vaccine prepared in Example 3 is safe for mice.

[0085] 2. Immunogenicity test of triple subunit vaccine against porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus in mice

[0086] (1) Immunization program

[0087] 1) Thirty-six 6-week-old female Balb / C mice were purchased and randomly divided into three groups, 12 mice in each group, A, B, and C. Each mouse in group A was subcutaneously injected with 0.2 ml of the triple subunit vaccine prepared in Example 3; each mouse in group B was subcutaneously injected with 0.2 ml of the porcine transmissible gastroenteritis and porcine epidemic diarrhea bivalent inactivated vaccine (Fumeri); each mouse in group C was subcutaneously injected with 0.2 ml of PBS buffer in the back, and the injection cycle was week 0, week 2, and week 4.

[0088] (2) Detection of specific antibody levels in mouse serum

[0089] 1) The blood collected from the tail vein was placed in a 37°C incubator for 30 minutes, placed at 4°C for 4 hours, centrifuged at 3000 rpm / min at 4°C for 10 minutes, and the serum was collected and packaged. The mouse specific antibody level was detected by indirect ELISA. The results are as follows Figure 6 A in Figure 6 B and Figure 6 As shown in C. Compared with group C, groups A and B can produce specific IgG antibodies after immunization, which is significantly different and can stimulate mice to produce specific IgG antibodies. The peak antibody duration of group A is longer than that of group B, and group A, as a triple subunit vaccine, has the advantages of safer vaccine ingredients and more antiviral types compared to group B's two-inactivated vaccine.

[0090] (3) Detection of neutralizing antibodies in mouse serum

[0091] 1) Detect the neutralizing antibody titers of specific viruses in the serum of each group at week 1, week 3, week 5, week 7, week 9, and week 11. The serum was inactivated at 56°C. LLC-PK1, ST, and VERO cell suspensions were inoculated in 96-well plates and cultured at a constant temperature for 24 hours; serum was incubated at 2 3Based on the initial dilution multiple, 100 TCID 50 100 TCID 50 TGEV virus solution was mixed and incubated; 100 TCID 50 The mixture was inoculated into the cell plate and duplicate wells were set. The cytopathic effect was observed daily and the number of CPE cells was recorded. The neutralizing antibody titer was calculated by the Reed-Muench method to evaluate the neutralizing effect of the serum on the virus. Figure 7 A in Figure 7 B and Figure 7 As shown in C. The neutralizing antibody titers of Group A and Group B gradually increased with time, reaching the highest peak in the 9th week and began to decline in the 11th week, which was significantly different from Group C. Both groups were able to produce specific neutralizing antibodies. The neutralizing antibody titers of Group A and Group B showed significant differences in the 9th week in the TGEV group, and Group A was able to simultaneously stimulate the body to produce neutralizing antibodies against three viruses: PEDV, PDCoV, and TGEV. Group B was only able to simultaneously stimulate the body to produce neutralizing antibodies against two viruses: PEDV and TGEV.

[0092] (4) Detection of mouse cytokine levels

[0093] According to the instructions of the CBA test kit, multi-factor detection was performed on mouse serum and lymphocyte stimulation supernatant. The steps are as follows:

[0094] 1) Open a bottle of lyophilized mouse Th1 / Th2 standard. Transfer the standard pellet to a 15 mL tube. Label the tube "Top Standard".

[0095] 2) Reconstitute the standards with 2.0 mL of Assay Diluent; label eight 12 x 75 mm tubes and arrange in the following order: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256; pipette 300 μL of Assay Diluent into each tube.

[0096] 3) Add each capture bead to the EP tube labeled "Mixed Capture Beads", vortex to mix the capture beads; add the mixed capture beads to the sample to be tested. Incubate at room temperature in the dark for 2 hours; add 1 mL of wash buffer to each assay tube, centrifuge at 200g for 5 minutes, and discard the supernatant.

[0097] 4) Add 300 μL of washing buffer, resuspend, and test on the instrument.

[0098] Cytokine level test results Figure 8 A in Figure 8 B and Figure 8 As shown in C, the contents of IFN-γ and IL-2 in group A were significantly higher than those in group B and group C. The content of IL-5 in group B was significantly higher than that in group A and group C. The results showed that group A induced a stronger Th1 type cellular immune response, while group B induced a stronger Th2 type cellular immune response.

[0099] (5) Mouse lymphocyte proliferation test

[0100] 1) Take the isolated mouse spleen lymphocytes for proliferation test, add 50 μL of diluted lymphocytes to each well of a 96-well plate. Each mouse is set up with three replicates, namely, a ConA nonspecific stimulation group, a protein-specific stimulation group, and a non-stimulated cell control group.

[0101] ConA diluent: Dissolve 10 mg of powder in 10 mL of deionized water and dispense into EP tubes at a concentration of 1 mg / mL. Then dilute 100 times to a final concentration of 10 μg / mL and store at -80°C away from light.

[0102] 500 μg / ml protein diluent: PEDV S COE The protein content is 4.7mg / mL and the purity is 91.3%. 1 ml contains 100% PEDV S COE The protein is about 4.2911mg, and 116.52μL of protein solution is mixed with 883.48μL of DMEM culture medium. RBD The protein content is 4.07 mg / mL, and the purity is 95%. 1 mL contains 100% PDCoV S RBD The protein is about 3.8665 mg. 129.32 μL of protein solution is mixed with 870.68 μL of DMEM culture medium. TGEV S AD The protein content is 3.6mg / mL and the purity is 90.4%. 1 ml contains 100% TGEV S AD The protein is about 3.2544 mg. 153.63 μL of protein solution was aspirated and mixed with 846.37 μL of DMEM culture medium. ConA diluent, 500 μg / ml protein diluent, and DMEM culture medium were added to 50 μL / well respectively. After mixing, the 96-well cell plate was placed in a cell culture incubator containing 5% CO2 at 37°C for 24 hours. 10 μL of CCK-8 solution was added to each well under light-proof conditions and placed in the cell culture incubator for 4 hours. The OD value was read at 450 nm by an enzyme reader, and the SI index of lymphocyte proliferation was calculated. GraphPad Prism 8.0 software was used for data analysis. The SI calculation formula is as follows: SI = (OD value of specific stimulation well - OD value of non-stimulated cell control well) / (OD value of non-specific stimulation well - OD value of non-stimulated cell control well) The results are as follows. Fig. 9 A in Fig. 9 B in Fig. 9 As shown in C. Group A and Group B were significantly higher than Group C. There was no significant difference between Group A and Group B in the ability of the body to respond to antigens again.

[0103] (6) Mouse spleen-specific CTL activity detection

[0104] The LDH release method was used to detect the specific CTL killing activity of mice. The steps are as follows:

[0105] 1) Take the mouse spleen lymphocyte suspension, count the cells and set aside. These cells are effector cells.

[0106] 2) LLC-PK1, ST, and VERO cells were inoculated into different 96-well plates and cultured in a 37°C 5% CO2 incubator until the cells grew to about 90%;

[0107] 3) 100 TCID 50 PDCoV, TGEV, and PEDV were inoculated into susceptible cells as target cells and cultured in a 37°C 5% CO2 incubator for 6 h;

[0108] 4) Inoculate lymphocytes at a ratio of 25:1 between effector cells and target cells. No lymphocytes are added to the natural release wells of effector cells, but only culture medium is added. The cell wells containing cell lysate are the maximum release wells. Incubate at 37°C and 5% CO2 for 4 h. Aspirate 100 μL of supernatant from each well, centrifuge and add to a new 96-well plate.

[0109] 5) Prepare working solution of lactic acid solution, 1×INT solution and enzyme solution in a ratio of 1:1:1, take 60 μL and add them to the 96-well plate containing samples, mix well; incubate at room temperature in the dark for 30 minutes, and measure the absorbance at 490 nm;

[0110] 6) CTL = [(absorbance of treated sample - absorbance of sample control well) / (absorbance of maximum cell enzyme activity - absorbance of sample control well)] × 100%. The results are as follows Fig.10 A in Fig.10 B and Fig.10 As shown in C. Group A and Group B were significantly higher than Group C.

[0111] (7) Flow cytometry detection of CD4 + T cell content and proliferation content after protein stimulation

[0112] 1×10 6 The separated spleen cells were added to a 12-well plate and PEDV S COE Protein, PDCoV S RBD Protein, TGEVS ADProtein was used to stimulate for 24 h, with 12.5 μg each, and three replicates were performed in each group. Flow cytometry was used to detect CD4 + Cell proliferation. The specific steps are as follows:

[0113] 1) 1×10 6 The separated spleen cells were dispensed into 1.5 ml EP tubes; centrifuged at 1000 rpm / min for 10 min at room temperature; the liquid was discarded, leaving about 100 μL of cell culture medium to fully resuspend the cells;

[0114] 2) Add cell surface markers FITC-CD3 and PE-CD4 and incubate at room temperature in the dark for 30 minutes; after the incubation, the spleen cells are centrifuged again, the culture medium is discarded, and DPBS is added for washing;

[0115] 3) Add 700 μL of cell culture medium to fully resuspend the cells and test on the instrument. Fig.11 A in Fig.11 B and Fig.11 As shown in C. Group A and Group B were significantly higher than Group C.

[0116] (8) Flow cytometry detection of CD8 + T cell proliferation and proliferation content after protein stimulation

[0117] 1×10 6 The separated spleen cells were added to a 12-well plate and stimulated with 12.5 μg of protein for 24 h. Each group was repeated three times. Flow cytometry was used to detect the CD8 + Cell proliferation. The specific steps are as follows:

[0118] 1) 1×10 6 The separated spleen cells were dispensed into 1.5 ml EP tubes; centrifuged at 1000 rpm / min for 10 min at room temperature; the liquid was discarded, leaving about 100 μL of cell culture medium to fully resuspend the cells;

[0119] 2) Add cell surface markers FITC-CD3 and APC-CD8 and incubate at room temperature in the dark for 30 minutes; after the incubation, the spleen cells are centrifuged again, the culture medium is discarded, and DPBS is added for washing;

[0120] 3) Add 700 μL of cell culture medium to fully resuspend the cells and test on the instrument. Fig.12 A in Fig.12 B and Fig.12 As shown in C. Group A and Group B were significantly higher than Group C.

[0121] in conclusion:

[0122] Compared with the commercialized two-unit inactivated virus vaccine of group B, group A has simpler and safer vaccine ingredients and more antiviral types, as well as neutralizing antibody titer, lymphocyte proliferation, CTL activity detection, CD4 + T cells, CD8 + There was no significant difference in T cell content between group A and group B, and the results of specific antibody IgG detection showed that the antibody peak duration of group A was longer than that of group B.

[0123] Example 5

[0124] Experimental study on the immune effect of triple subunit vaccine against porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus on pigs

[0125] 1. Immunogenicity test of triple subunit vaccine against porcine epidemic diarrhea virus, porcine deltacoronavirus and porcine transmissible gastroenteritis virus in pigs

[0126] (1) Immunization program

[0127] Fifteen healthy piglets of 1 week old were purchased and randomly divided into three groups, 5 in each group, A, B, and C. Each piglet in group A was subcutaneously injected with 2 ml of the triple subunit vaccine prepared in Example 3; each piglet in group B was subcutaneously injected with 2 ml of the bivalent inactivated vaccine for porcine transmissible gastroenteritis and porcine epidemic diarrhea (Fumetrix); each piglet in group C was subcutaneously injected with 2 ml of PBS buffer in the back, and the injection cycle was week 0 and week 2.

[0128] (2) Detection of specific antibody levels in piglet serum

[0129] The blood collected from the anterior vena cava was placed in a 37°C incubator for 30 minutes, placed at 4°C for 4 hours, and centrifuged at 3000rpm / min at 4°C for 10 minutes. The serum was drawn and packaged, and the level of piglet-specific antibodies was detected by indirect ELISA. Compared with group C, both groups A and B were able to produce specific IgG antibodies after immunization, which was significantly different and could stimulate piglets to produce specific IgG antibodies.

[0130] (3) Detection of neutralizing antibodies in piglet serum

[0131] The neutralizing antibody titers against specific viruses in the sera of each group were detected at week 1, week 3, week 5, week 7, week 9, and week 11. The sera were inactivated at 56°C. LLC-PK1, ST, and VERO cell suspensions were inoculated in 96-well plates and cultured at a constant temperature for 24 hours; 3 Based on the initial dilution multiple, 100 TCID 50 100 TCID 50TGEV virus solution was mixed and incubated; 100 TCID 50 The mixture was incubated with the PEDV virus liquid. The incubated mixture was inoculated into the cell plate and duplicate wells were set up. The cytopathic effect was observed daily and the number of CPE cells was recorded. The neutralizing antibody titer was calculated by the Reed-Muench method to evaluate the neutralizing effect of the serum on the virus. The neutralizing antibody titers in Group A and Group B gradually increased with time, which was significantly different from Group C, and both groups were able to produce specific neutralizing antibodies. Group A can simultaneously stimulate the body to produce neutralizing antibodies against three viruses: PEDV, PDCoV, and TGEV. Group B can only simultaneously stimulate the body to produce neutralizing antibodies against two viruses: PEDV and TGEV.

[0132] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A triple subunit vaccine for porcine epidemic diarrhea virus, porcine deltacoronavirus, and porcine transmissible gastroenteritis virus, It is characterized in that The triple subunit vaccine comprises an antigen and an immune adjuvant; the antigen comprises porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD protein.

2. The triple subunit vaccine according to claim 1, It is characterized in that Porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD The nucleotide sequences of the protein genes after optimization of baculovirus codon preference are SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively.

3. The triple subunit vaccine according to claim 1, It is characterized in that The porcine epidemic diarrhea virus S COE Protein, porcine deltacoronavirus S RBD TGEV-S AD The mass ratio of the proteins is (2~4):(2~4):(2~4).

4. The triple subunit vaccine according to claim 1, It is characterized in that In each dose of the triple subunit vaccine, porcine epidemic diarrhea virus S COE The amount of protein used is 20-40 μg, porcine delta coronavirus S RBD The dosage of protein is 20-40 μg, and the amount of porcine transmissible gastroenteritis virus S AD The amount of protein used is 20 to 40 μg.

5. The triple subunit vaccine according to claim 1, It is characterized in that The immune adjuvants include ISA201 VG adjuvant and CPG 2395 immune enhancer.

6. The triple subunit vaccine according to claim 5, It is characterized in that The mass ratio of ISA201 VG adjuvant to antigen was 1:1; the volume percentage of CPG 2395 immune enhancer added was 5%.

7. The triple subunit vaccine according to claim 1, It is characterized in that The pH value of the triple subunit vaccine is 7.6-8.

2.

8. A method for preparing the triple subunit vaccine according to any one of claims 1 to 7, The following steps are involved: Under sterile conditions, the antigen and immune adjuvant are mixed to obtain a triple subunit vaccine.

9. The preparation method according to claim 8, It is characterized in that The method for preparing the antigen comprises the following steps: The gene sequences of the antigens after baculovirus codon preference optimization were cloned into baculovirus transfer vectors to obtain recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD; The recombinant baculovirus vectors pFastbacHTA-COE, pFastbacHTA-RBD and pFastbacHTA-SAD are respectively transferred into competent cells DH10Bac, cultured, screened, and extracted to obtain recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD; The recombinant shuttle bacmids Bacmid-COE, Bacmid-RBD and Bacmid-SAD were transfected into SF9 cells, respectively, to rescue the recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD; The recombinant baculoviruses Ac MNPV-COE, Ac MNPV-RBD and Ac MNPV-SAD were inoculated into Hi-five cells, the cells were ultrasonically disrupted, the supernatant was centrifuged and the antigen PEDV-S was obtained by ion exchange chromatography. COE Protein, PDCoV-S RBD Protein and TGEV-S AD protein.

10. The preparation method according to claim 8, It is characterized in that The immune adjuvant includes ISA 201 VG adjuvant and CPG 2395 immune enhancer, the mass ratio of ISA201 VG adjuvant to antigen is 1:1; the volume percentage of CPG 2395 immune enhancer added is 5%.

Citation Information

Cited By

  • Porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus triple mRNA vaccine and preparation method thereof

    CN122251568A

  • Recombinant TGEV and PDCOV bivalent subunit vaccine as well as preparation method and application thereof

    CN122461444A